Frontiers in Pharmacology
Cure8 research brief
Why This Matters
The study explores whether blood redox biomarkers relate to short- and long-term response to infliximab or vedolizumab, which could help predict who benefits from these biologics. It also suggests a link between glutathione and iron metabolism that may be biologically relevant.
Who Should Pay Attention
Clinicians, researchers, and patients on biologic therapy (infliximab or vedolizumab) interested in biomarkers of treatment response.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The authors report modest, mostly non-significant differences in several redox markers between responders and non-responders, with some suggestion that cysteine and homocysteine differed in infliximab-treated patients and that free thiols rose in short-term responders but fell in non-responders.
Glutathione showed an inverse correlation with transferrin saturation and serum iron after induction, suggesting a link between redox status and iron metabolism.
The study is exploratory and relatively small (n=58) and the reported biomarker differences were largely non-significant; the authors conclude these markers may warrant further study in larger prospective cohorts before clinical use.
Keep In Mind
Exploratory, small sample (n=58) and most differences were non-significant; findings require validation in larger prospective studies.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationFrontiers in Pharmacology
PublisherFrontiers Media SA
AuthorsSem Geertsema, Roberta Loveikyte, Sofie de Jong +6 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedOct 14, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Circulating microRNAs as biomarkers of disease activity and treatment response in Crohn’s disease patients receiving infliximab or vedolizumab: a longitudinal cohort study
If validated, blood microRNAs could become noninvasive biomarkers to help track inflammation and predict biochemical response to infliximab or vedolizumab in Crohn’s disease, complementing CRP and fecal calprotectin.
Long-term efficacy and safety of vedolizumab compared with infliximab in biologic-naive ulcerative colitis: a systematic review and meta-analysis
This meta-analysis pooled long‑term comparative data suggesting vedolizumab may have advantages over infliximab for treatment persistence, 12‑month remission, and safety in biologic‑naive ulcerative colitis — information...
Differential long-term efficacy of biologic and small-molecule therapies by disease location in moderate-to-severe luminal Crohn's disease: a systematic review and network meta-analysis.
The analysis suggests that some biologic and small-molecule therapies work differently depending on whether Crohn's disease affects the ileum, colon, or both — information that could help tailor long-term treatment...